IMRT Course 2016

Neoadjuvant (NHT) and/or adjuvant (AHT) hormone

therapy

•

NHT, before definitive local treatment with curative intent, aims:

–

To reduce tumour bulk and prostate volume. Short-term ADT

(3-4 m) reduces prostate size by 25-50%;

this may allow more

focused RT

–

To treat micrometastatic disease and the primary lesion

•

NHT responders may be candidates for AHT after surgery or RT

•

NHT and/or AHT plus RT improves disease progression and/or

overall survival vs. RT alone in high-risk localized and locally

advanced PCa

•

Intermediate-risk patients may also benefit from combined RT

and short-term ADT